RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.